Pfizer secures FDA approval for Hemophilia B gene therapy BEQVEZ

Pfizer Inc. (NYSE: PFE) announced a significant breakthrough in hemophilia treatment with the U.S. Food and Drug Administration's approval of BEQVEZ (fidanacogene elaparvovec-dzkt), a pioneering ... Read More